Antimalarials and electrocardiographic alterations: New data bring confidence

Published On 2022-06-05 14:30 GMT | Update On 2022-06-05 14:31 GMT

Previous findings on the link between hydroxychloroquine and risk of arrhythmia have been contradictory, with low-level evidence-based results. To address this, Md Rashedul Hoque and colleagues in Arthritis Research Canada and Simon Fraser University ran a large cohort study. The group identified 11,518 hydroxychloroquine initiators with newly diagnosed with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), and assessed the risk of incident arrhythmia. The results were presented at the 2022 EULAR Congress in Copenhagen.

Over mean follow-up of 8 years, there were 1,610 and 1,646 incident arrhythmias in the initiator and non-initiator groups, respectively – giving crude incidence rates of 17.5 and 18.1 per 1,000 person-years. This suggests no increased risk of any type of arrhythmia among new users of hydroxychloroquine.

Dr Carmen Riesco Bárcena also presented findings on the possible relationship between antimalarial drugs and electrocardiographic alterations in people with SLE. In this cross-sectional study of 91 patients, 4.69% of those on current antimalarials had a prolonged QTc, compared to 3.7% of those without current treatment.

Further investigation showed a statistically significant association between taking antimalarial drugs and the elongated QTc interval. However, multivariate analysis suggested there was no significant relationship between electrocardiographic alterations and treatment with antimalarials.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Antimalarials and electrocardiographic alterations: New data bring confidence

Similar News

Midazolam Reduces Breathing Flexibility, While S-Ketamine Preserves It: Pilot Trial Finds

Early SSRF Reduces Mortality and Improves Outcomes in Functionally Dependent Rib Fracture Patients: Study

OTC Access to Oral Contraceptives May Improve Equitable Contraception Use: JAMA

Normal BMI Doesn’t Mean Low Risk: Study Links Diabetes to Fatty Liver in Lean Individuals

Beta-Blockers After MI in Patients with LVEF Above 40%: Findings of BETAMI-DANBLOCK Trial Presented at ESC Congress 2025

Lower Irisin Levels Linked to Diabetic Nephropathy Progression in T2DM: Study

Androgenic anabolic steroids exposure associated with coronary atherosclerosis and MI: JAMA

Sex Influences Quality-of-Life Outcomes in Peanut Oral Immunotherapy: Study